SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-073072
Filing Date
2024-06-13
Accepted
2024-06-13 16:30:15
Documents
13
Period of Report
2024-06-11
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20240613.htm   iXBRL 8-K 74938
2 EX-3.1(A) lctx-ex3_1a.htm EX-3.1(A) 250559
3 EX-3.1(B) lctx-ex3_1b.htm EX-3.1(B) 396418
  Complete submission text file 0000950170-24-073072.txt   935125

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20240613.xsd EX-101.SCH 24844
17 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20240613_htm.xml XML 4697
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 241041664
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)